AB-110 is under clinical development by Angiocrine Bioscience and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AB-110’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AB-110 overview

AB-110 is under development for the treatment of high risk hematologic malignancies include sickle cell disease, myelodysplastic syndrome, acute lymphocytic leukemia (ALL, acute lymphoblastic leukemia) and acute myelocytic leukemia (AML, acute myeloblastic leukemia). It is composed of human umbilical cord blood derived hematopoietic stem and progenitor cells co-cultured and expanded with proprietary E-CEL UVEC cells.

Angiocrine Bioscience overview

Angiocrine Bioscience (Angiocrine) is a cellular therapy company that develops novel treatments based on its proprietary E-CEL technology platform. The company’s pipeline products include E-CEL PEC, E-CEL TEC and E-CEL UVEC. Its E-CEL technology comprises of stem cells and vascular cultured endothelial cells genetically modified by the insertion of the adenovirus E4ORF1 gene. Angiocrine’s E-CEL PEC is used for the treatment of moderate to severe COPD and other lung diseases. The company’s E-CEL UVEC is used for the treatment of high-risk hematologic malignancy and sickle cell diseases. It partners with pharmaceutical and biotechnology companies for its novel drug development. Angiocrine is headquartered in San Diego, California, the US.

For a complete picture of AB-110’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.